David Woldbye, born 1963, is Associate Professor at the University of Copenhagen, where, among other things, he leads a research group at the Laboratory of Neural Plasticity, Department of Neuroscience and Pharmacology. He was the first to demonstrate that NPY has an anti-epileptic effect in vivo, and has published a large number of scientific papers on this subject and related research areas.
Merab Kokaia, born 1956, is Professor of Neurophysiology and heads the Epilepsy Centre, Lund University Faculty of Medicine. In addition to his research collaboration with David Woldbye, concerning NPY and epilepsy, Merab Kokaia has also led breakthrough studies concerning optogenetics and neurotrophins in the context of epilepsy. He also contributed to the scientific discoveries and patented inventions upon which the companies NeuroVive Pharmaceutical AB (publ) and MaasBiolab in the USA were established.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.